TP53 and adenocarcinoma: In this paper, we present a relatively simple molecular technique called restriction site mutation (RSM) (Jenkins et al, 1999,2001a,2001b) and assess its ability to detect early p53 mutations in premalignant Barrett's tissues from patients without clinically detectable adenocarcinoma.